Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.63 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | STAT3 | P40763 | 3/20 | 0.52 |
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26813317 | 0.97 | CRBN (0.64) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL2384063 | 0.94 | CRBN (0.68) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL23702573 | 0.90 | CRBN (0.66) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL25189934 | 0.90 | CRBN (0.66) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL30376233 | 0.90 | CRBN (0.66) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL23702535 | 0.90 | CRBN (0.66) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL21331487 | 0.89 | CRBN (0.65) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL26832141 | 0.89 | CRBN (0.65) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL23702554 | 0.89 | CRBN (0.67) | CRBNDDB1EGFRHDAC1HDAC2 | |
| SCHEMBL23751748 | 0.88 | CRBN (0.63) | CRBNDDB1EGFRHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 1386/4885DDB1 328/4885EGFR 2112/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | CRBN 1386/4885DDB1 328/4885EGFR 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.